3 Penny Stocks to Watch Now, 12/18/25
TipRanks (Thu, 18-Dec 9:25 AM ET)
3 Penny Stocks to Watch Now, 12/16/25
TipRanks (Tue, 16-Dec 10:29 AM ET)
FDA Clears HeartBeam’s Cable-Free 12-Lead ECG—A Game Changer for At-Home Heart Monitoring?
Market Chameleon (Fri, 12-Dec 4:54 AM ET)
Game-Changing News: BEAT, APRE, TOON, MNTS, PRSO, PNPNF, SIGL - Stocks Under $1 Look Now
AB Digital Inc (Thu, 11-Dec 3:06 PM ET)
Market Chameleon (Thu, 11-Dec 5:30 AM ET)
Business Wire (Wed, 10-Dec 7:00 AM ET)
Market Chameleon (Fri, 28-Nov 4:52 AM ET)
Business Wire (Wed, 26-Nov 4:32 PM ET)
HeartBeam Reports Third Quarter 2025 Results
Business Wire (Thu, 13-Nov 4:01 PM ET)
Business Wire (Thu, 30-Oct 7:00 AM ET)
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
Heartbeam trades on the NASDAQ stock market under the symbol BEAT.
As of December 18, 2025, BEAT stock price declined to $2.94 with 3,375,134 million shares trading.
BEAT has a beta of 1.11, meaning it tends to be more sensitive to market movements. BEAT has a correlation of 0.02 to the broad based SPY ETF.
BEAT has a market cap of $101.26 million. This is considered a Micro Cap stock.
Last quarter Heartbeam reported $0 in Revenue and -$.15 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.01.
In the last 3 years, BEAT traded as high as $5.74 and as low as $.54.
The top ETF exchange traded funds that BEAT belongs to (by Net Assets): VTI, VXF, IWC.
BEAT has underperformed the market in the last year with a return of +5.8%, while SPY returned +13.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BEAT shares. However, BEAT has outperformed the market in the last 3 month and 2 week periods, returning +108.5% and +317.4%, while SPY returned +3.5% and -0.5%, respectively. This indicates BEAT has been having a stronger performance recently.
BEAT support price is $2.70 and resistance is $3.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BEAT shares will trade within this expected range on the day.